Complications at usage of the new anticoagulant therapy in elderly patients

Introduction: New anticoagulant therapy (DOAC) was introduced few years ago. It is an alternative therapy for antagonists of vitamin K (VKA) in prevention and therapy of diseases with different etiology. Despite their advantages, bleeding stays a major complication. The fact is that there are no sig...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Trailov Dunja, Despotović Nebojša
Formato:	article
Lenguaje:	EN SR
Publicado:	University of Belgrade, Medical Faculty 2021
Materias:	new anticoagulant therapy bleeding elderly Medicine R
Acceso en línea:	https://doaj.org/article/90ff93d3c1c74db385530f38acba431c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:90ff93d3c1c74db385530f38acba431c
record_format	dspace
spelling	oai:doaj.org-article:90ff93d3c1c74db385530f38acba431c2021-12-05T21:26:44ZComplications at usage of the new anticoagulant therapy in elderly patients0369-15272466-552510.5937/mp72-27624https://doaj.org/article/90ff93d3c1c74db385530f38acba431c2021-01-01T00:00:00Zhttps://scindeks-clanci.ceon.rs/data/pdf/0369-1527/2021/0369-15272102001T.pdfhttps://doaj.org/toc/0369-1527https://doaj.org/toc/2466-5525Introduction: New anticoagulant therapy (DOAC) was introduced few years ago. It is an alternative therapy for antagonists of vitamin K (VKA) in prevention and therapy of diseases with different etiology. Despite their advantages, bleeding stays a major complication. The fact is that there are no significant researches on this topic. Aim: To analyze the incidence of bleeding as a complication in patients treated with dabigatran. Material and methods: A retrospective study was conducted including 60 patients older than 65 years with nonvalvular atrial fibrillation treated with anticoagulant therapy. Half of this number was taking dabigatran (examined group) and half was taking warfarin (control group). Apart from demographical and clinical parameters, incidence, type and localization of bleeding was also followed. Results: In the group of patients who were taking dabigatran, in 13.3% of cases bleeding occurred as a complication of therapy. Among them, gastrointestinal bleeding was the most common (75%), but also hematomas on the body occurred (25%) and the therapy was immediately discontinued. In 45% of patients taking warfarin, bleeding was verified as a complication. From that number, 33.5% had gastrointestinal bleeding and epistaxis, 8.6% hematomas and 24.4% hematuria. By comparing these two groups, it can be concluded that incidence of bleeding in the group taking dabigatran was significantly lower than in the group taking warfarin (p = 0.038). Conclusion: In the examined group of patients older than 65, who were taking dabigatran, a significantly lower percentage of bleeding as a complication was noticed, compared to the control group taking VKA.Trailov DunjaDespotović NebojšaUniversity of Belgrade, Medical Facultyarticlenew anticoagulant therapybleedingelderlyMedicineRENSRMedicinski Podmladak, Vol 72, Iss 2, Pp 1-4 (2021)
institution	DOAJ
collection	DOAJ
language	EN SR
topic	new anticoagulant therapy bleeding elderly Medicine R
spellingShingle	new anticoagulant therapy bleeding elderly Medicine R Trailov Dunja Despotović Nebojša Complications at usage of the new anticoagulant therapy in elderly patients
description	Introduction: New anticoagulant therapy (DOAC) was introduced few years ago. It is an alternative therapy for antagonists of vitamin K (VKA) in prevention and therapy of diseases with different etiology. Despite their advantages, bleeding stays a major complication. The fact is that there are no significant researches on this topic. Aim: To analyze the incidence of bleeding as a complication in patients treated with dabigatran. Material and methods: A retrospective study was conducted including 60 patients older than 65 years with nonvalvular atrial fibrillation treated with anticoagulant therapy. Half of this number was taking dabigatran (examined group) and half was taking warfarin (control group). Apart from demographical and clinical parameters, incidence, type and localization of bleeding was also followed. Results: In the group of patients who were taking dabigatran, in 13.3% of cases bleeding occurred as a complication of therapy. Among them, gastrointestinal bleeding was the most common (75%), but also hematomas on the body occurred (25%) and the therapy was immediately discontinued. In 45% of patients taking warfarin, bleeding was verified as a complication. From that number, 33.5% had gastrointestinal bleeding and epistaxis, 8.6% hematomas and 24.4% hematuria. By comparing these two groups, it can be concluded that incidence of bleeding in the group taking dabigatran was significantly lower than in the group taking warfarin (p = 0.038). Conclusion: In the examined group of patients older than 65, who were taking dabigatran, a significantly lower percentage of bleeding as a complication was noticed, compared to the control group taking VKA.
format	article
author	Trailov Dunja Despotović Nebojša
author_facet	Trailov Dunja Despotović Nebojša
author_sort	Trailov Dunja
title	Complications at usage of the new anticoagulant therapy in elderly patients
title_short	Complications at usage of the new anticoagulant therapy in elderly patients
title_full	Complications at usage of the new anticoagulant therapy in elderly patients
title_fullStr	Complications at usage of the new anticoagulant therapy in elderly patients
title_full_unstemmed	Complications at usage of the new anticoagulant therapy in elderly patients
title_sort	complications at usage of the new anticoagulant therapy in elderly patients
publisher	University of Belgrade, Medical Faculty
publishDate	2021
url	https://doaj.org/article/90ff93d3c1c74db385530f38acba431c
work_keys_str_mv	AT trailovdunja complicationsatusageofthenewanticoagulanttherapyinelderlypatients AT despotovicnebojsa complicationsatusageofthenewanticoagulanttherapyinelderlypatients
_version_	1718371015341375488

Complications at usage of the new anticoagulant therapy in elderly patients

Ejemplares similares